CN117363652B - Dual-transcription factor regulated dual-start plasmid, nano material, preparation method and application thereof - Google Patents
Dual-transcription factor regulated dual-start plasmid, nano material, preparation method and application thereof Download PDFInfo
- Publication number
- CN117363652B CN117363652B CN202311301531.XA CN202311301531A CN117363652B CN 117363652 B CN117363652 B CN 117363652B CN 202311301531 A CN202311301531 A CN 202311301531A CN 117363652 B CN117363652 B CN 117363652B
- Authority
- CN
- China
- Prior art keywords
- dual
- plasmid
- cnp
- pphs
- regulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 69
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000002086 nanomaterial Substances 0.000 title abstract description 32
- 238000013518 transcription Methods 0.000 title description 4
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 49
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 49
- 230000009977 dual effect Effects 0.000 claims abstract description 27
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 36
- 210000004881 tumor cell Anatomy 0.000 abstract description 31
- 101100043050 Mus musculus Sox4 gene Proteins 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 230000006907 apoptotic process Effects 0.000 abstract description 13
- 230000033228 biological regulation Effects 0.000 abstract description 11
- 102100037388 Gasdermin-D Human genes 0.000 abstract description 9
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 abstract description 9
- 238000002619 cancer immunotherapy Methods 0.000 abstract description 8
- 239000012634 fragment Substances 0.000 abstract description 8
- 238000010353 genetic engineering Methods 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 239000011572 manganese Substances 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 56
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 42
- 239000002539 nanocarrier Substances 0.000 description 33
- 239000002105 nanoparticle Substances 0.000 description 29
- 210000000170 cell membrane Anatomy 0.000 description 23
- 229910000019 calcium carbonate Inorganic materials 0.000 description 21
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 14
- 229910052748 manganese Inorganic materials 0.000 description 14
- 238000011534 incubation Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100037387 Gasdermin-A Human genes 0.000 description 6
- 101001026276 Homo sapiens Gasdermin-A Proteins 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 208000024798 heartburn Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920001510 poly[2-(diisopropylamino)ethyl methacrylate] polymer Polymers 0.000 description 5
- 208000024981 pyrosis Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 108090000426 Caspase-1 Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102100025597 Caspase-4 Human genes 0.000 description 2
- 101710090338 Caspase-4 Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 238000003222 MTT reduction assay Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 101150000845 GSDMD gene Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000409 membrane extraction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the fields of genetic engineering and biological medicine, and particularly discloses a dual-promoter plasmid and a nano material regulated by dual transcription factors, and a preparation method and application thereof. According to the invention, a recombinant plasmid for specifically expressing the pyroprotein based on the regulation and control of Sox4 and Hif-1 alpha dual transcription factors is constructed for the first time, and the CDS region of GSDMD and clear-caspase-1 (P20-P10) genes and the combined promoter sequence of Sox4 and Hif-1 alpha are cloned to the plasmid by a genetic engineering means to obtain the dual-promoter plasmid regulated and controlled by the dual transcription factors, so that GSDMD is specifically expressed in tumor cells and active fragments are released, and the purpose of accurately treating tumors is achieved. Based on the recombinant plasmid, the invention also provides a nano material regulated by double transcription factors and a preparation method thereof, and the effect of cancer immunotherapy is enhanced by precisely inducing tumor cell apoptosis.
Description
Technical Field
The invention belongs to the fields of genetic engineering and biological medicine, and in particular relates to a double-start plasmid and a nano material regulated and controlled by double transcription factors, and a preparation method and application thereof.
Background
Pyrodeath is a programmed cell death pattern mediated by GASDERMIN (GSDM) protein family, which occurs in dependence on caspase 1/4/5/11 (caspase-1/4/5/11), which performs in dependence on GSDM protein family, which is cleaved by caspase-1 into N-and C-terminal domains, the N-terminal domain being perforated on the cell membrane, resulting in cell swelling and cell rupture, forming a bubble-like structure of plasma membrane pores, further resulting in release of pro-inflammatory substances such as interleukin 1 beta and 18 (interleukin beta/18, IL-1 beta/18) to extracellular stimuli with strong inflammatory response.
Recent studies have shown that pyrosis triggers the release of endogenous danger signals and tumor-associated antigens, can generate an effective and durable anti-tumor immune response, and suggest that induction of pyrosis has become a promising strategy for promoting cancer immunotherapy. For example, strategies for enhancing cancer immunotherapy using chemotherapeutic agents, as well as some inorganic nanomaterials to induce pyro-death, have been widely studied. However, these strategies still face challenges such as limited efficacy and systemic toxicity, mainly due to low bioavailability and non-specific biodistribution, thus limiting the immune response induced by pyrosis. Therefore, the GSDM protein can enhance the specific expression of the tumor site, accurately activate the scorch of tumor cells, and provide a promising approach for improving tumor immunotherapy. Delivery of a plasmid encoding GSDM protein, which enhances its expression in tumor cells to induce tumor cell apoptosis, may be a potential strategy for treating cancer. However, the indiscriminate expression of GSDM protein can cause the scorch of normal cells, thereby causing systemic toxic and side effects.
In order to realize tumor specific expression of target protein, chinese patent CN114657210B (Zhongshan Da Sun Yixian commemorative hospital) discloses a nanomaterial based on a N-terminal peptide of a load GSDMD protein, wherein a material core is GSDMD-N plasmid, a GSDMD-N-terminal sequence (shown as SEQ ID NO: 2) is loaded, and the entrapment material is nano-carrier PDPA, in particular Meo-PEG-B-PDPA with weak acid response. The patent synthesizes brominated polyethylene glycol (Meo-PEG-Br) firstly, then synthesizes Meo-PEG-b-PDPA by utilizing an atom transfer radical polymerization method, then mixes GSDMD-N plasmid with G0-C14 solution, and then mixes the mixture with Meo-PEG-b-PDPA to obtain GSDMD-N-PDPA nano material. As GSDMD-N has the functions of tumor killing and potential inherent immune chemotactic, the prepared nano material has the functions of tumor killing and local immune function enhancement, and can effectively promote the release of plasmids once entering an acidic tumor microenvironment, so that a large amount of inherent immune cell chemokines in tumor cells are obviously increased. In addition, the physiological characteristics of tumor endogenous including pH, certain enzymes and redox potential are well developed for plasmid-targeted delivery and protein-specific expression, and Mn, one of microelements essential for human body, also shows good effects in promoting antigen presentation, activating innate immune response. Therefore, the development of efficient and tumor-specific cell apoptosis strategies is critical to promote cancer immunotherapy.
Disclosure of Invention
The invention mainly solves the technical problem of providing a double-start plasmid for expressing the pyroprotein GSDMD and the clear-caspase-1 (P20-P10) based on the regulation and control of Sox4 and Hif-1 alpha double transcription factors.
Secondly, the invention provides a nano material based on Sox4 and Hif-1 alpha dual transcription factor regulation and control and a preparation method thereof, so as to realize accurate induction of tumor cell apoptosis, thereby enhancing the effect of cancer immunotherapy.
The invention further provides application of the double-start plasmid and the nano material regulated by the double transcription factors in preparing medicaments for treating cancers.
In order to solve the technical problems, the invention provides the following technical scheme:
A dual transcription factor regulated dual promoter plasmid comprising elements linked in the following order: hif-1 alpha transcription factor binding site-clear-caspase-1 gene CDS region-Sox 4 transcription factor binding site-GSDMD gene CDS region.
As a preferred embodiment of the present invention, the plasmid comprises elements linked in the following order: hif-1. Alpha. Transcription factor binding site-clear-caspase-1 gene CDS region-SV 40 Poly (A) termination signal-Sox 4 transcription factor binding site-GSDMD gene CDS region-SV 40 Poly (A) termination signal.
As a preferred embodiment of the present invention, the NCBI accession number of the clear-caspase-1 gene is NM-009807.2.
As a preferred embodiment of the present invention, the GSDMD gene has NCBI accession number NM-026960.4.
As a preferred embodiment of the invention, the plasmid comprises a sequence as set forth in SEQ ID NO:1, corresponding to elements linked in the following order: hif-1. Alpha. Transcription factor binding site-clear-caspase-1 gene CDS region-SV 40Poly (A) termination signal-Sox 4 transcription factor binding site-GSDMD gene CDS region-SV 40Poly (A) termination signal.
As a preferred embodiment of the present invention, the plasmid is a plasmid having a sequence as set forth in SEQ ID NO:1, and a nucleotide sequence shown in the formula 1.
As a preferred embodiment of the present invention, the nucleotide sequence of the plasmid is shown in SEQ ID NO: 2.
The nano material comprises an inner core, wherein the inner core comprises calcium carbonate nano particles and double-start plasmids regulated by double transcription factors, and the double-start plasmids regulated by the double transcription factors are uniformly distributed on the surfaces of the calcium carbonate nano particles.
As a preferred embodiment of the present invention, the calcium carbonate nanoparticle is loaded with manganese. During preparation, manganese is firstly loaded on the calcium carbonate nano-particles, and then the manganese is mixed with the double-start plasmid regulated by the double transcription factors, so that the double-start plasmid regulated by the double transcription factors is uniformly distributed on the surfaces of the calcium carbonate nano-particles loaded with manganese.
As a preferred embodiment of the present invention, the nanomaterial comprises an outer membrane layer that is wrapped around the outer surface of the inner core. Specifically, the outer membrane layer is composed of cell membrane vesicles. Sources of the cell membrane vesicles include, but are not limited to, MC38 cells, and also can be encapsulated using erythrocyte membranes and the like. Further, targeting substances, such as folic acid, can be added to the adventitia layer to increase the targeting of tumors.
As a preferred embodiment of the present invention, the nanomaterial is sized from 100 to 200nm.
A preparation method of a nano material regulated by double transcription factors comprises the following steps: mixing the calcium carbonate nano particles and the dual-start plasmids regulated by the dual transcription factors in the solution to obtain the inner core of the nano material.
As a preferred embodiment of the present invention, the method further comprises: manganese is firstly loaded on the calcium carbonate nano particles, and then the manganese is mixed with double-start plasmids regulated by double transcription factors.
As a preferred embodiment of the present invention, the method further comprises: mixing and extruding the inner core of the nano material with the cell membrane vesicle to obtain the nano material.
As a preferred embodiment of the present invention, the calcium carbonate nanoparticles are prepared using a gas diffusion process, or are commercially available. Specifically, the preparation method of the calcium carbonate nano-particles comprises the following steps: dispersing calcium salt (such as CaCl 2) in absolute ethanol by ultrasonic, and reacting with ammonium bicarbonate (NH 4HCO3) at room temperature to obtain calcium carbonate nano-particles.
As a preferred embodiment of the present invention, the preparation method of the manganese-loaded calcium carbonate nanoparticle comprises the following steps: dispersing manganese salt (such as MnCl 2) in absolute ethanol, adding calcium carbonate nanoparticles, and mixing.
As a preferred embodiment of the invention, the preparation method of the inner core of the nano material comprises the following steps: mixing manganese-loaded calcium carbonate nanoparticles and dual-initiation plasmids regulated by dual transcription factors in a solution (such as PBS buffer solution).
As a preferred embodiment of the invention, the preparation method of the cell membrane vesicle comprises the following steps: and carrying out ultrasonic treatment on the extracted cell membrane fragments, and then extruding to obtain the cell membrane derivative vesicles, namely the cell membrane vesicles.
An application of dual-transcription factor regulated dual-start plasmid or dual-transcription factor regulated nano material in preparing the medicines for treating cancer.
As a preferred embodiment of the invention, the medicament is prepared into a pharmaceutically acceptable dosage form by adopting pharmaceutically acceptable auxiliary materials. Such adjuvants include, but are not limited to, wetting agents, excipients, antioxidants, preservatives, and the like. Such dosage forms include, but are not limited to, injections, tablets, dispersions, suspensions, and the like.
As a preferred embodiment of the invention, the medicament is used for inducing the scorch of tumor cells and enhancing the effect of cancer immunotherapy.
The invention has the beneficial effects that:
The invention constructs a recombinant plasmid for specifically expressing the pyroprotein based on the regulation of Sox4 and Hif-1 alpha dual transcription factors for the first time, clones the CDS region of GSDMD and clear-caspase-1 (P20-P10) genes and the combined promoter sequence of Sox4 and Hif-1 alpha to the plasmid through a genetic engineering means to obtain the dual-promoter plasmid regulated by the dual transcription factors, so as to realize the specific expression GSDMD in tumor cells and release active fragments, thereby achieving the purpose of accurately treating tumors.
The invention also provides a nano material based on Sox4 and Hif-1 alpha dual transcription factor regulation and control, and a preparation method and application thereof, so as to realize accurate induction of tumor cell apoptosis, thereby enhancing the effect of cancer immunotherapy.
Drawings
FIG. 1 is a map of plasmid pPHS design in experimental example.
FIG. 2 shows the size of plasmid pPHS in experimental example by agarose gel electrophoresis;
in the figure, the left lane: control plasmid (2300 bp), right lane: plasmid pPHS (6348 bp).
FIG. 3 shows flow cytometry validation pPHS of regulated P20-P10-His and GSDMD-Flag protein expression in experimental examples;
In the figure, a: P20-P10-His protein expression, B: GSDMD-Flag protein expression.
FIG. 4 shows the killing ability of MC38 by flow cytometry analysis pPHS in the experimental example.
FIG. 5 is a schematic diagram of the construction flow of the nanocarrier M-CNP/Mn@pPHS in experimental example.
FIG. 6 shows the particle size distribution and Zeta potential distribution of the nanocarriers in the experimental example;
In the figure, A-B: particle size distribution of CNP/MnNPs and nanocarriers, C: zeta potential profiles of different nano-formulations.
FIG. 7 is a transmission electron microscope image of the nanocarrier in the experimental example;
In the figure, a: transmission electron micrograph of CNP/MnNPs, B: M-CNP/Mn@pPHS transmission electron microscope image.
FIG. 8 is a PDI diagram of the nanocarrier in experimental example.
FIG. 9 is a graph showing the analysis of the uptake capacity of tumor cells on nanocarriers in experimental examples;
in the figure, a: flow chart after incubation of M-CNP/Mn@pPHS with MC38 cells, B: CLSM image.
FIG. 10 shows relative cell viability (n=3) of MC38 cells treated with different concentrations (0, 20, 40, 60 and 80. Mu.g/mL) of CNP/Mn, CNP/Mn@pPHS, MCNP@pPHS and M-CNP/Mn@pPHS in experimental examples.
FIG. 11 is a phase contrast microscope image of experimental examples after incubation of M-CNP/Mn@pPHS (20. Mu.g/mL) with MC38, MC38 shSox4, MC38 shSox4 and MC38 shSox 4/shHif-1. Alpha. Cells for 24h, respectively;
in the figure, red arrows indicate scorched cells.
FIG. 12 shows the results of the detection of cytotoxicity and tumor cell apoptosis in experimental examples;
In the figure, A-B: detecting apoptosis by a flow cytometer based on annexin v-FITC/PI; c: morphological photographs after different drugs treatment of MC38 cells, wherein M-CNP/Mn@pPHS treatment group cells were swollen, large bubble-like structures (black arrows), scale: 25 μm; d: lactate dehydrogenase kit detects (LDH) release.
FIG. 13 shows the tumor volume and body weight of MC38 tumor-bearing mice in different treatment groups in the experimental example.
In order to more clearly illustrate the technical solution of the embodiments of the present invention, the above description of the drawings obtained in the experimental examples is briefly described. It is to be understood that the above-described drawings illustrate only some examples of the invention and are not to be considered limiting of the scope of the claims. Other relevant drawings may be made by those of ordinary skill in the art without undue burden from these drawings.
Detailed Description
The technical scheme of the present invention will be clearly and completely described in the following in connection with specific examples and experimental examples. It should be understood by those skilled in the art that the examples are only for illustrating the technical scheme of the present invention and should not be construed as limiting the scope of the present invention. All other embodiments, such as modified, modified or simply substituted embodiments, which would be apparent to one of ordinary skill in the art without undue effort based on the examples described below, are intended to be within the scope of the present invention.
The experimental methods used in the following examples and experimental examples are all conventional methods unless otherwise specified; the raw materials (including biological materials), reagents, media, instruments, etc. used, unless otherwise specified, are all commonly used in the art, publicly available or commercially available; the terms and abbreviations are all the conventional meanings in the art, such as PBS for phosphate buffer, and PBST for phosphate Tween buffer.
Example 1
The present example provides a dual promoter plasmid regulated by dual transcription factors, comprising elements linked in the following order: hif-1 alpha transcription factor binding site-clear-caspase-1 gene CDS region-SV 40 Poly (A) termination signal-Sox 4 transcription factor binding site-GSDMD gene CDS region-SV 40 Poly (A) termination signal (nucleotide sequence shown as SEQ ID NO: 1).
In other embodiments of the invention, the plasmid is a plasmid inserted between Pci I and Not I of the pEGFP-N1 vector as shown in SEQ ID NO:1, and a nucleotide sequence shown in the formula 1.
Example 2
The embodiment provides a dual-promoter plasmid regulated by dual transcription factors, the nucleotide sequence of which is shown in SEQ ID NO: 2.
Example 3
The embodiment provides a nano material regulated by double transcription factors, which comprises an inner core and an outer film layer, wherein the inner core comprises manganese-loaded calcium carbonate nano particles and double-start plasmids regulated by double transcription factors, and the double-start plasmids regulated by the double transcription factors are uniformly distributed on the surfaces of the manganese-loaded calcium carbonate nano particles; the outer membrane layer is wrapped on the outer surface of the inner core and is composed of cell membrane vesicles; the size of the obtained nano material is 100-200nm.
The embodiment provides a preparation method of a nano material regulated by double transcription factors, which comprises the following steps:
preparing calcium carbonate nano particles by adopting a gas diffusion method;
Dispersing MnCl 2 in absolute ethyl alcohol, adding calcium carbonate nano particles, and mixing to load manganese on the mixture;
Mixing manganese-loaded calcium carbonate nano particles and dual-start plasmids regulated by dual transcription factors in PBS buffer solution to obtain a nano material core;
mixing and extruding the cell membrane vesicle with the inner core to obtain the nano material.
In other embodiments of the invention, the nanomaterial comprises only an inner core comprising manganese-loaded calcium carbonate nanoparticles and dual transcription factor-regulated dual-start plasmids, wherein the dual transcription factor-regulated dual-start plasmids are uniformly distributed on the surface of the manganese-loaded calcium carbonate nanoparticles.
Example 4
The embodiment provides an application of a nano material regulated by double transcription factors in preparing a medicament for treating cancer, and in particular relates to the application of the nano material regulated by double transcription factors in preparing the medicament for treating cancer:
The nanometer material is mixed with excipient, preservative and other pharmaceutically acceptable supplementary material to prepare medicine injection for inducing tumor cell death and enhancing cancer immunological treatment effect.
In other embodiments of the invention, dual transcription factor regulated dual promoter plasmids are used to prepare medicaments for the treatment of cancer.
Experimental example
1. Design, synthesis and verification of plasmid pPHS
1.1, Complete plasmid design map and sequence
The plasmid map is shown in FIG. 1, and the plasmid full sequence is shown as follows (or shown as SEQ ID NO: 2):
GGATCCGGACGTGGGGTAAGGACGTGGGGTAAGGACGTGGGGTAAGGACGTGGGGTAAGGACGTGGGGTAAGGACGTGGGGTAAGAGGGTATATAATGGAATTCATGAACAAAGAAGATGGCACATTTCCAGGACTGACTGGGACCCTCAAGTTTTGCCCTTTAGAAAAAGCCCAGAAGTTATGGAAAGAAAATCCTTCAGAGATTTATCCAATAATGAATACAACCACTCGTACACGTCTTGCCCTCATTATCTGCAACACAGAGTTTCAACATCTTTCTCCGAGGGTTGGAGCTCAAGTTGACCTCAGAGAAATGAAGTTGCTGCTGGAGGATCTGGGGTATACCGTGAAAGTGAAAGAAAATCTCACAGCTCTGGAGATGGTGAAAGAGGTGAAAGAATTTGCTGCCTGCCCAGAGCACAAGACTTCTGACAGTACTTTCCTTGTATTCATGTCTCATGGTATCCAGGAGGGAATATGTGGGACCACATACTCTAATGAAGTTTCAGATATTTTAAAGGTTGACACAATCTTTCAGATGATGAACACTTTGAAGTGCCCAAGCTTGAAAGACAAGCCCAAGGTGATCATTATTCAGGCATGCCGTGGAGAGAAACAAGGAGTGGTGTTGTTAAAAGATTCAGTAAGAGACTCTGAAGAGGATTTCTTAACGGATGCAATTTTTGAAGATGATGGCATTAAGAAGGCCCATATAGAGAAAGATTTTATTGCTTTCTGCTCTTCAACACCAGATAATGTGTCTTGGAGACATCCTGTCAGGGGCTCACTTTTCATTGAGTCACTCATCAAACACATGAAAGAATATGCCTGGTCTTGTGACTTGGAGGACATTTTCAGAAAGGTTCGATTTTCATTTGAACAACCAGAATTTAGGCTACAGATGCCCACTGCTGATAGGGTGACCCTGACAAAACGTTTCTACCTCTTCCCGGGACATCATCATCACCATCACCATCATCACCATCACTAACTCGAGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCTAGAAGAAGAACAAAGGACTAGGGTAAAGAAGAACAAAGGACTAGGGTAAAGAAGAACAAAGGACTAGGGTAAAGAAGAACAAAGGACTAGGGTAAAGAAGAACAAAGGACTAGGGTAAAGAAGAACAAAGGACTAGGGTAAGAGGGTATATAATGAGATCTATGCCATCGGCCTTTGAGAAAGTGGTCAAGAATGTGATCAAGGAGGTAAGCGGCAGCAGAGGCGATCTCATTCCGGTGGACAGCCTGCGGAACTCCACCAGCTTCAGGCCCTACTGCCTTCTGAACAGGAAATTTTCAAGCTCAAGGTTCTGGAAACCCCGTTATTCATGTGTCAACCTGTCAATCAAGGACATCCTGGAGCCCAGTGCTCCAGAACCAGAACCGGAGTGTTTTGGCTCCTTCAAAGTCTCTGATGTCGTCGATGGGAACATTCAGGGCAGAGTGATGTTGTCAGGCATGGGAGAAGGGAAAATTTCTGGTGGGGCTGCAGTGTCTGACAGTTCCAGTGCCTCCATGAATGTGTGTATACTGCGTGTGACTCAGAAGACCTGGGAGACCATGCAGCATGAAAGGCACCTTCAGCAGCCTGAGAACAAAATCCTGCAACAGCTTCGGAGTCGTGGGGATGACCTGTTTGTGGTGACCGAGGTGCTGCAGACAAAGGAGGAAGTGCAGATCACTGAGGTCCACAGCCAAGAGGGCTCAGGCCAGTTTACGCTGCCTGGAGCTTTATGCTTGAAGGGTGAAGGCAAGGGCCACCAAAGCCGGAAGAAGATGGTGACCATTCCTGCAGGCAGCATCCTGGCATTCCGAGTGGCCCAACTGCTTATTGGCTCTAAATGGGATATCCTTCTCGTCTCAGATGAGAAACAGAGGACCTTTGAGCCCTCCTCAGGTGACAGAAAAGCAGTGGGCCAGAGGCACCATGGCCTCAATGTGCTTGCTGCGCTTTGTTCCATCGGAAAGCAGCTCAGTCTCCTGTCAGATGGGATTGATGAGGAGGAATTAATTGAGGCGGCAGACTTCCAGGGCCTGTATGCTGAGGTGAAGGCTTGCTCCTCAGAACTGGAGAGCTTGGAAATGGAGTTGAGACAACAGATACTGGTGAACATCGGAAAGATTTTACAGGACCAGCCCAGCATGGAAGCCTTAGAGGCCTCACTAGGGCAGGGCCTGTGCAGTGGCGGCCAGGTGGAGCCTCTGGACGGCCCAGCTGGCTGCATCCTTGAGTGTCTGGTGCTTGACTCTGGAGAACTGGTGCCGGAACTCGCAGCCCCTATCTTCTACCTGCTGGGAGCACTGGCTGTGCTGAGTGAAACCCAGCAGCAGCTGCTAGCTAAGGCTCTGGAGACAACGGTGCTGTCAAAGCAGCTGGAGTTGGTGAAGCACGTCTTGGAACAGAGCACCCCGTGGCAGGAGCAGAGTTCTGTGTCCCTGCCCACCGTGCTCCTTGGGGACTGCTGGGATGAAAAGAATCCCACCTGGGTCTTGCTAGAAGAATGTGGCCTAAGGCTGCAGGTAGAATCCCCCCAGGTGCACTGGGAACCAACGTCTCTGATCCCCACAAGTGCGCTCTATGCCTCCCTGTTCCTATTGTCAAGTCTAGGCCAGAAACCTTGTGATTACAAGGATGACGACGATAAGGACTATAAGGACGATGATGACAAGGACTACAAAGATGATGACGATAAATAAAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGT.
1.2 Synthesis and extraction of plasmids
The binding promoter sequences of clear-caspase-1 (P20-P10) (NCBI accession number: NM-009807.2) and GSDMD (NCBI accession number: NM-026960.4) gene CDS region, and Sox4 and Hif-1α were cloned into two cleavage sites of Pci I and NotI of pEGFP-N1 vector, and complete gene synthesis and subcloning were accomplished by Hua Dada gene company. Plasmid pPHS is synthesized and cloned into DH5 alpha coliform bacteria to preserve strain, and then shake-bacteria amplification is carried out in LB liquid medium. The extraction of plasmid pPHS was performed according to the experimental procedures of the commercial kit. The extracted plasmid is stored in a refrigerator at-20 ℃ after the concentration is measured.
1.3, Agarose gel electrophoresis to verify if the plasmid construction was successful
Washing the glue making mold and the comb with distilled water, placing the glue making mold and the comb on a glue making flat plate, closing the edge of the mold, and inserting the comb. Agarose gel (1%) of appropriate concentration was prepared with gel buffer according to the size of the DNA fragment to be isolated: accurately weighing 0.30g of agarose dry powder, adding the powder into a triangular flask for preparing gel, and quantitatively adding 30mL of electrophoresis buffer. Heating and melting in a microwave oven, cooling for a while, adding red fluorescent nucleic acid dye (EB) 3 μl, slightly rotating to mix thoroughly, rapidly pouring into an electrophoresis tank, adding 10×volume sample buffer loadingbuffet into DNA sample, and adding corresponding amount of triple distilled water for diluting and mixing. After 30 minutes (30-45 minutes) at room temperature, the gel was completely coagulated, the comb was carefully pulled out, the sample and Marker were added to the gel well, and the gel was placed in the electrophoresis tank. The electrophoresis buffer, such as bubbles in the sample well, is poured into the electrophoresis tank and the bubbles are removed. Then, the power supply is switched on, red is the positive electrode, black is the negative electrode, the DNA sample swims from the negative electrode to the positive electrode (one end close to the sample adding hole is negative), and electrophoresis conditions are set: 120V,300mA, for 30min, the results are shown in FIG. 2.
1.4, Verification of plasmid expression
The procedure for plasmid expression verification was as follows:
1) The MC38 cell line was transfected by calcium phosphate transfection.
2) MC38 cells are spread one day in advance, and transfection is performed when the cells grow to about 90%.
3) Medium (DMEM medium with 10% FBS) was replaced 0.5h (0.5-1 h) before transfection, and 1.5mL in 6-well plates.
4) Prepare 1.5mL tube, split into A, B tubes:
i.A pipe: 180 mu L of water, 20 mu L of calcium chloride solution and 2 mu g of skeleton plasmid are blown and evenly mixed;
tube b: 200. Mu. LHBS buffer.
5) The tube A was placed on an oscillator, the gun was adjusted to 70. Mu.L, HBS in the tube B was added dropwise to the tube A3 times, slowly in the dropwise addition, immediately after each addition, air was blown in and mixed thoroughly, and the mixture was left to stand for 5 minutes after all addition.
6) The mixture was added dropwise to MC38 cells and cultured in an incubator.
7) After 6h (all 6-8 h) of transfection the medium (containing 10% FBS serum) was replaced.
8) The expression of the target protein was detected in a post-flow manner for 36h (24-48 h is available), and the result is shown in FIG. 3.
1.5 Functional verification of plasmid
The transfection is used for verifying whether the target plasmid can induce cell apoptosis, and the operation steps are as follows:
1) The empty plasmid without the target fragment of the core of the pyroptoprotein is used as a negative control, and the plasmid is designed as an experimental group. The experimental groups were taken for annexin V-PE and 7-AAD single staining, respectively, for adjustment of compensation.
2) The adherent cells and the supernatant thereof were collected, the cells were digested with pancreatin free of EDTA, the cells were collected after termination of the digestion, and centrifuged at 3500rpm at 4℃for 5min, and the supernatant was discarded.
3) Washing the cells: the cells were washed twice with pre-chilled PBS, centrifuged at 3500rpm at 4℃for 5min each, and the supernatant discarded. Cell resuspension: mu.L of 1 Xbinding Buffer was added and gently swirled until a single cell suspension was obtained.
4) Cell staining: add 5. Mu.L Annexin V-PE and 5. Mu.L 7-AAD STAINING Solution (both commercial kit), gently blow and incubate for 10min at room temperature (20-25 ℃) in the dark, then add 400. Mu.L 1 Xbinding Buffer, gently mix.
5) The stained sample was examined with a flow cytometer within 1 hour, and the results are shown in fig. 4.
2. Construction of M-CNP/Mn@pPHS nano-carrier
The M-CNP/Mn@pPHS nano-carrier is constructed by the following steps (the preparation flow is shown in figure 5):
1) Preparing a calcium carbonate nano carrier by using a gas diffusion method: accurately weighing CaCl 2, adding into a beaker containing absolute ethyl alcohol, uniformly dispersing CaCl 2 in the absolute ethyl alcohol by ultrasonic treatment, placing the beaker and the other 4 beakers containing NH 4HCO3 into a vacuum dryer, reacting at room temperature for 48 hours, centrifuging to obtain CNP, dispersing in an absolute ethyl alcohol solution containing MnCl 2, repeatedly centrifuging and washing, and collecting pure CNP/Mn.
2) Uniformly dispersing the obtained CNP/Mn into PBS, proportionally adding pPHS, stirring for 12 hours by a magnetic stirrer, and centrifugally collecting CNP/Mn@pPHS nano particles.
3) Extracting MC38 cell membrane with commercial cell membrane extraction kit, selecting MC38 cell in logarithmic growth phase, and extracting cell membrane from MC38 cell according to kit instruction to obtain cell membrane fragments.
4) MC38 cell membrane fragments were sonicated in ddH 2 O and then extruded with an extruder to give cell membrane vesicles. The cancer cell membrane vesicles were mixed with the above-collected nanoparticles, and simultaneously extruded multiple times with an extruder (pore size 200 nm) to obtain M-CNP/Mn@pPHS.
3. Characterization of nano drug delivery systems
3.1 Analysis of Zeta potential
Detecting Zeta potential and particle size distribution of the nano carrier: the sample was suspended in ddH 2 O (1 mg/mL), and after 10min of sonication the size distribution and Zeta potential of the nanoparticles were measured by Zetasizer Nano ZS (Malvern, nano ZS, U.K.), the results are shown in FIG. 6.
3.2 Topography testing of nanocarriers
The Transmission Electron Microscope (TEM) is used for characterizing the nano material, and the specific method is as follows: the copper mesh was placed on a filter paper, 100. Mu.L of the nano-carrier prepared in advance was extracted with a pipette, dropped on the copper mesh, repeated 3 times of operation, and then dried in an oven, and the morphology of the nano-particles was observed by TEM (HT 7700, hitachi, japan), and the result is shown in FIG. 7.
3.3 Analysis of nanocarrier stability
An appropriate amount of nanocarriers were weighed and ultrasonically dispersed in sterile water, and their hydrated particle size and PDI were measured daily with a Markov particle sizer and continuously examined for 7 days, the results of which are shown in FIG. 8.
3.4, Encapsulation efficiency of nano-carrier and drug-loading rate measurement
Separating free medicine in nano carrier and supernatant by differential centrifugation, firstly setting different mass ratios of M-CNP/Mn and pPHS to prepare M-CNP/Mn@pPHS, and then centrifuging at 10000rpm and 4 ℃ for 60min, and collecting supernatant; the obtained supernatant was subjected to double-strand DNA concentration detection using Equalbit X dsDNA HS detection kit and Qubit TM Flex fluorometer, and the encapsulation efficiency and drug loading rate were calculated using the following formulas, and the results are shown in Table 1.
3.5 Activity study of nanodelivery System at cellular level
3.5.1 Investigation of cell uptake Capacity
In order to observe the uptake condition of the cells on the nano material, the uptake level of the tumor cells on the nano drug carrying system is estimated, firstly, a 5-FAM fluorescent marked M-CNP/Mn@5-FAM nano carrier is prepared, MC38 cells with good growth state are selected, the density is adjusted to be 1X 10 5 cells/hole, the cells are paved in a confocal culture dish, and then the cells are placed in a 5% CO 2 and 37 ℃ incubator for overnight culture. After the culture is finished, discarding the old culture medium at the upper layer, adding the prepared fluorescent nano carrier M-CNP/Mn@5-FAM and MC38 cells for incubation, discarding the supernatant after incubation for 1,2 and 4 hours, washing 2 times by PBS, and adding PBS buffer solution containing DAPI for incubation for 30min. After the incubation, the dish bottom was washed 3 times with PBS, put into a light-shielding wet box, and taken to a laser confocal microscope for observation of the uptake, and the result is shown in FIG. 9.
3.5.2 MTT reduction method
Cytotoxicity was assessed using a typical MTT reduction assay: cells were first seeded into 96-well plates, dosed after cell attachment, and different treatment groups were set: CNP/Mn group, CNP/Mn@pPHS group, M-CNP@pPHS group, M-CNP/Mn@pPHS group, PBS group, and different concentrations were set: 0. 20, 40, 60 and 80. Mu.g/mL. At time points 24, 48 and 72 hours, 20 mu LMTT of solution is added, after 4 hours of incubation in dark place, 150 mu L of dimethyl sulfoxide (DMSO) is added into each hole, the mixture is placed on an oscillator to oscillate in dark place, finally, the absorbance of each hole is measured at the wavelength of 490nm by an enzyme-labeling instrument, the cell survival rate of each experimental group is calculated respectively, so as to evaluate the toxicity of the constructed nano-carrier to normal cells and TNBC cells, and the experiment is repeated for 3 times, and the result is shown in figure 10.
3.5.3 Verification of tumor-specific pyrosis induced by nano-carrier M-CNP/Mn@pPHS
A. Construction of stable Sox4 and Hif-1 alpha MC38 cells knocked down singly or simultaneously
1) The company synthesized shSox and shHif-1α were subcloned between the Age I and EcoR I cleavage sites of the pLVX-puro vector.
2) Lentiviruses were generated in HEK-293T and host cell MC38 was infected with the virus.
3) After 48 hours incubation puromycin (0.1 mg/mL) was added and empty vector was transferred to cells as negative control.
4) After lentivirus transfection and puromycin screening, each group of cellular RNAs was extracted and the knock-out efficiency was detected by RT-qPCR.
B. Observing the influence of M-CNP/Mn@pPHS on normal and tumor cell lines by a phase contrast microscope
1) MC38, CHO-K1, RAW264.7, BMDC, MC38 shSox4, MC38 shHif-1α, MC38 shSox/shHif-1α cell lines with good growth status were selected, density was adjusted to 2X 10 5 cells/well plated in 6-well plates, and then placed in a 37℃incubator containing 5% CO 2 for overnight culture.
2) After the completion of the culture, the old medium was discarded, and M-CNP/Mn@pPHS (20. Mu.g/mL) prepared in advance was added to the medium to incubate MC38 cells, respectively.
3) After 24h incubation, the change in morphology of each group of cells was observed using a phase contrast microscope and stored with photographs, the results of which are shown in fig. 11.
C. M-CNP/Mn@pPHS induced cell apoptosis verification
Annexin-V/PI staining experiments, lactate Dehydrogenase (LDH) release experiments, and microscopic observation of tumor cell death morphology were analyzed by flow cytometry, and the results are shown in FIG. 12.
3.7, Establishment of C57BL/6 mouse subcutaneous colon cancer tumor model
Study of in vivo anticancer effects with female C57BL/6 mice to construct MC38 subcutaneous tumor models MC38 cells were resuspended in 200 μ LPBS and injected subcutaneously on the right back of the mice. After 7 days, mice were randomly divided into 5 groups and, after tumor growth to 40-80mm 3, mice were given intravenous injections of PBS, CNP/Mn, CNP/Mn@pPHS, M-CNP@pPHS, and M-CNP/Mn@pPHS. The medicines are injected again at intervals of 3 days, the administration is carried out 5 times, the tumor volume and the weight change of the mice are monitored every 1 day, and the in-vivo treatment effect of the medicines is observed through the monitoring of the indexes. After the treatment, mice were sacrificed in section and tumor tissues were removed for photographing, and 1 mouse tumor, heart, liver, spleen, lung, kidney, etc. were taken for each group for H & E analysis, and the results are shown in fig. 13.
The tumor volume calculation formula is as follows:
Tumor volume (mm 3) =length×width 2/2; wherein the length is the longest dimension and the width is the vertical dimension.
4. Experimental results
4.1, Particle size, zeta potential
The physicochemical properties of the prepared different nano-carriers are characterized by adopting a plurality of technical means, as shown in figures 6A-6B, dynamic Light Scattering (DLS) results show that the hydrodynamic diameter of CNP/MnNPs is 100.46+/-0.82 nm; TEM observes that M-CNP/Mn@pPHS wrapped by cell membrane has a complete membrane structure with a diameter of about 150nm, and dynamic light scattering results show that the hydrodynamic diameter is 153.17 + -1.69 nm, which is about 50nm larger than that of CNP/Mn due to the wrapping by cell membrane.
The Zeta potential (Zetapotential) is the potential of the shear plane (SHEAR PLANE), also known as the electrokinetic or electrokinetic potential, and is an important indicator for the stability of colloidal dispersions. As shown in FIG. 6C, analysis of the Zeta potential of each nanoparticle involved in the preparation process revealed that the Zeta potentials of CNP/Mn@pPHS and M-CNP/Mn@pPHS were reduced from 7.83.+ -. 0.34mV to-24.33.+ -. 1.11mV and-32.63.+ -. 0.67mV, respectively, which may be related to the load of pPHS which is negatively charged and the coating of the cell membrane.
4.2 Topographical features of nanocarriers
From the transmission electron microscope images of FIGS. 7A-7B, it can be observed that CNP/MnNPs, M-CNP/Mn@pPHS all exhibit a monodispersed state and are spherical in size. Compared with CNP/MnNPs, the surface of M-CNP/Mn@pPHS is obviously coated with a layer of transparent substance, which proves that the coating of MC38 cell membranes is successful, and the loading rate of the nano drug delivery system is more stable.
4.3 Stability analysis of nanocarriers
As shown in FIG. 8, the particle size and PDI value of M-CNP/Mn@pPHS remained relatively stable by PDI detection for 7 consecutive days, demonstrating that the nanocarriers remained well stable and dispersible in sterile water within 7 days.
4.4, Encapsulation efficiency of nano-carrier and drug-loading rate measurement
In order to obtain better encapsulation efficiency and drug loading rate of the nano-carrier, different proportions are designed for measurement. As shown in Table 1, at a mass ratio of 10:1, the encapsulation efficiency of pPHS reached a maximum.
TABLE 1 encapsulation efficiency and drug loading of nanocarriers
4.5, Analysis of cellular uptake Capacity
In order to evaluate the uptake of the nanocarriers by tumor cells, the tumor cells were analyzed by flow cytometry using 5-FAM labeled nanoparticles followed by incubation with MC38 tumor cells. As shown in FIG. 9, the degree of internalization of M-CNP/Mn@5-FAM by tumor cells increased with increasing culture time. Quantitative analysis shows that the uptake rate of M-CNP/Mn@5-FAM after 4h incubation is significantly higher than that of CNP/Mn@5-FAM, which is mainly attributed to the cell membrane layer mediated tumor targeting ability. Consistent with the flow cytometer results, the uptake results of confocal laser scanning microscopy evaluation showed that M-CNP/Mn@5-FAM showed brighter green fluorescence, representing an increase in cellular uptake.
4.6 MTT reduction assay to assess cytotoxicity
The result of evaluating the toxicity of the nanocarrier to normal cells is shown in fig. 10, and compared with the control group, the survival rate of the CNP/Mn to MC38 cells is not affected, which indicates that the nanoparticles have no effect on the activity of tumor cells, and meanwhile, the nanoparticles have no obvious proliferation inhibition to MC38 cells, which indicates that the CNP/Mn nanoparticles have good drug safety. The CNP/Mn@pPHS, M-CNP@pPHS and M-CNP/Mn@pPHS nano-carrier treatment groups containing pPHS gene medicaments have obvious influence on the cell survival rate, and particularly, the treatment of the M-CNP/Mn@pPHS leads to the cell activity to be obviously lower than that of other groups, and obviously inhibits the proliferation of tumor cells. The experimental result shows that the M-CNP/Mn@pPHS nano-carrier has obvious killing effect on tumor cells under the action of pPHS and has good medicinal safety.
4.7 Verification of tumor-specific apoptosis induced by nanocarrier M-CNP/Mn@pPHS
In order to study the accurate regulation and control effect of Sox4 and Hif-1 alpha dual transcription factors on tumor cell specific killing, MC38 cells in which Sox4 and Hif-1 alpha are knocked down singly or simultaneously are constructed. Together with MC38 tumor cell line, CHO-K1, RAW264.7 and BMDC, the important effect of Sox4 and Hif-1 alpha double transcription factor on accurate killing of tumor cells in M-CNP/Mn@pPHS treatment is explored. As shown in FIG. 11, M-CNP/Mn@pPHS can not induce the scorch of cells knocked down with Sox4 and Hif-1 alpha, and further proves that the specific tumor cell scorch induced by double regulation of Sox4 and Hif-1 alpha. MC38 cells knocked out of Sox4 or Hif-1 alpha and MC38 cells knocked out of Sox4 and Hif-1 alpha simultaneously survive, so that the cell morphology is clear, and the specific tumor cell pyrosis induced by double regulation of Sox4 and Hif-1 alpha is further confirmed. Single modulation means killing as long as responding to a high expression, and is easy to bring toxic and side effects. And Sox4 and Hif-1 alpha are over-expressed in tumor tissues, so that double regulation and control are more accurate and safer, and toxic and side effects and accidental injury to normal cells can be reduced.
4.8, Analysis of the cellular therapeutic Effect of the Nano drug delivery System
As shown in FIG. 9, after CNP/Mn@pPHS, M-CNP@pPHS, M-CNP/Mn@pPHS treatment, the coke death rate of tumor cells was significantly increased (FIG. 12A), and a large amount of LDH was released (FIG. 12B), while a bubble-like structure was present around MC38 cells (FIG. 12C). Compared with the CNP/Mn@pPHS group, the M-CNP/Mn@pPHS group has the further improved capability of inducing cell apoptosis, which indicates that the membrane coating can improve the phagocytosis of cells and enhance the capability of inducing cell apoptosis.
4.9, MC38 tumor volume Change in tumor-bearing mice
In order to explore the anti-tumor effect of M-CNP/Mn@pPHS in animals, a MC38 mouse subcutaneous transplantation tumor model is specifically constructed, and the experimental result is shown in FIG. 13. The results show that the tumor of the whole vector M-CNP/Mn@pPHS group is obviously smaller than that of other groups, the optimal anti-tumor effect is shown, and the weight of each group of mice is hardly changed during the treatment period, so that the normal life of the mice is not influenced by the nano vector.
In summary, the invention constructs a recombinant plasmid for specifically expressing the pyroprotein based on the regulation of Sox4 and Hif-1 alpha dual transcription factors for the first time, clones the CDS region of GSDMD and clear-caspase-1 (P20-P10) genes and the combined promoter sequence of Sox4 and Hif-1 alpha to the plasmid through a genetic engineering means to obtain the dual-promoter plasmid regulated by the dual transcription factors, so as to realize the specific expression GSDMD and release of active fragments in tumor cells, thereby achieving the purpose of accurately treating tumors. The nanomaterial based on Sox4 and Hif-1 alpha dual transcription factor regulation provided by the invention can accurately induce tumor cell apoptosis, enhance the effect of cancer immunotherapy, and has no obvious toxic or side effect.
Although the technical solutions of the present invention have been described in detail in the foregoing general description, the specific embodiments and the test examples, it should be noted that the examples and the test examples are only for illustrating the technical solutions and the technical effects of the present invention, and should not be construed as limiting the scope of the present invention. Simple variations, modifications or improvements made on the basis of the technical idea of the invention fall within the scope of the invention as claimed.
Claims (2)
1. A dual promoter plasmid regulated by dual transcription factors, characterized in that: the plasmid comprises the sequence as set forth in SEQ ID NO:1, corresponding to elements linked in the following order: hif-1 alpha transcription factor binding site-clear-caspase-1 gene CDS region-SV 40Poly (A) termination signal-Sox 4 transcription factor binding site-GSDMD gene CDS region-SV 40Poly (A) termination signal;
And/or, the plasmid is a plasmid inserted between Pci I and Not I of pEGFP-N1 vector as shown in SEQ ID NO:1, and the corresponding nucleotide sequence is shown as SEQ ID NO: 2.
2. Use of a dual promoter plasmid regulated by a dual transcription factor according to claim 1 for the preparation of a medicament for the treatment of colon cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311301531.XA CN117363652B (en) | 2023-10-10 | 2023-10-10 | Dual-transcription factor regulated dual-start plasmid, nano material, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311301531.XA CN117363652B (en) | 2023-10-10 | 2023-10-10 | Dual-transcription factor regulated dual-start plasmid, nano material, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117363652A CN117363652A (en) | 2024-01-09 |
| CN117363652B true CN117363652B (en) | 2024-06-07 |
Family
ID=89406966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311301531.XA Active CN117363652B (en) | 2023-10-10 | 2023-10-10 | Dual-transcription factor regulated dual-start plasmid, nano material, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117363652B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109136265A (en) * | 2018-09-25 | 2019-01-04 | 吉林大学 | GSDMD-N gene recombination plasmid and methods and applications in mammary carcinoma model |
| WO2021036793A1 (en) * | 2019-08-23 | 2021-03-04 | National Institute Of Biological Sciences, Beijing | Pyroptosis-induced immunotherapy |
| CN112939951A (en) * | 2021-01-29 | 2021-06-11 | 华南理工大学 | Cell apoptosis drug prodrug, preparation method thereof and cell apoptosis drug |
| CN112961857A (en) * | 2021-04-13 | 2021-06-15 | 上海中医药大学 | Non-coding long-chain RNA gene for mediating lung adenocarcinoma cell apoptosis |
| CN114657210A (en) * | 2022-03-03 | 2022-06-24 | 中山大学孙逸仙纪念医院 | Nano material based on GSDMD protein N-terminal peptide fragment loading and application thereof |
-
2023
- 2023-10-10 CN CN202311301531.XA patent/CN117363652B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109136265A (en) * | 2018-09-25 | 2019-01-04 | 吉林大学 | GSDMD-N gene recombination plasmid and methods and applications in mammary carcinoma model |
| WO2021036793A1 (en) * | 2019-08-23 | 2021-03-04 | National Institute Of Biological Sciences, Beijing | Pyroptosis-induced immunotherapy |
| CN112939951A (en) * | 2021-01-29 | 2021-06-11 | 华南理工大学 | Cell apoptosis drug prodrug, preparation method thereof and cell apoptosis drug |
| CN112961857A (en) * | 2021-04-13 | 2021-06-15 | 上海中医药大学 | Non-coding long-chain RNA gene for mediating lung adenocarcinoma cell apoptosis |
| CN114657210A (en) * | 2022-03-03 | 2022-06-24 | 中山大学孙逸仙纪念医院 | Nano material based on GSDMD protein N-terminal peptide fragment loading and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| "Logic "AND Gate Circuit"-Based Gasdermin Protein Expressing Nanoplatform Induces Tumor-Specific Pyroptosis to Enhance Cancer Immunotherapy";Xiaoxi Wang 等;《ACS NANO》;20240220;第18卷;第6946-6962页 * |
| "经典途径细胞焦亡模型的构建";傅心雨 等;《中国兽医学报》;20211130;第41卷(第11期);第2238-2242页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117363652A (en) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system | |
| Zhu et al. | Nanoparticle-enhanced generation of gene-transfected mesenchymal stem cells for in vivo cardiac repair | |
| CN103705465B (en) | Cancer target administration nano-drug administration system that a kind of micro-acid environment target polypeptide is modified and preparation method thereof | |
| Lu et al. | A biocompatible reconstituted high-density lipoprotein nano-system as a probe for lung cancer detection | |
| CN107375234A (en) | A kind of multifunctional carrier and preparation method and application based on cell source vesica in body fluid | |
| Tong et al. | Preparation of protamine cationic nanobubbles and experimental study of their physical properties and in vivo contrast enhancement | |
| CN109666695A (en) | A kind of excretion body carrier and its preparation method and application of targeted integration element α v β 3 | |
| Enomoto et al. | Viral protein-coating of magnetic nanoparticles using simian virus 40 VP1 | |
| CN115252582B (en) | Preparation and application of erythrocyte membrane heterozygous pH liposome coated oncolytic virus preparation | |
| CN113041356A (en) | Hemopsin targeting drug-loading system, preparation method and application thereof | |
| CN105561334A (en) | Temperature targeting-based nanogel gene delivery compound, and preparation method and application thereof | |
| Qiao et al. | Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy | |
| CN109550057A (en) | Active targeting type gene delivery nanoparticle and its preparation method and application | |
| CN117363652B (en) | Dual-transcription factor regulated dual-start plasmid, nano material, preparation method and application thereof | |
| CN110354096B (en) | Brain-targeted drug delivery system capable of improving drug-resistant brain glioma microenvironment and reversing drug resistance | |
| Qiao et al. | A brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles | |
| Zeng et al. | Biodegradable nano-organosilica gene carrier for high-efficiency gene transfection | |
| Gao et al. | Construction of PD-L1-siRNA and IL-2 DNA loading PEI lipid nanoparticles in activating T cells and treating lung cancer | |
| CN113105625B (en) | Succinic acid vitamin E modified polyethyleneimine derivative, and preparation method and application thereof | |
| CN105535988A (en) | Preparation method and antitumor enhancement application of dual-targeting delivery chemotherapeutic drug nanosystem | |
| CN101524548A (en) | Nanometer carrier combination and application thereof to preparation of anti-tumor drug | |
| CN112426537A (en) | Polypeptide nano micelle and preparation method and application thereof | |
| CN117512008A (en) | Recombinant plasmid capable of accurately inducing tumor cell apoptosis and application thereof | |
| CN115634214B (en) | Injectable hydrogel/polyphenol miRNA carrier slow-release system and preparation method and application thereof | |
| Ma et al. | Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |